Earnings season is now starting to wind down, with most companies already having reported their quarterly results. But there are still some companies left to report, and Dendreon Corporation (NASDAQ:DNDN) is about to release its quarterly earnings report. The key to making smart investment decisions with stocks releasing their quarter reports is to anticipate how they’ll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you’ll be less likely to make an uninformed kneejerk reaction to news that turns out to be exactly the wrong move.
Stats on Dendreon
Analyst EPS Estimate | ($0.56) |
Year-Ago EPS | $0.26 |
Revenue Estimate | $82.9 million |
Change From Year-Ago Revenue | 7.7% |
Earnings Beats in Past 4 Quarters | 1 |
Source: Yahoo! Finance.
Will Dendreon cure its ills this quarter?
Analysts haven’t budged on their estimates for Dendreon, but they aren’t terribly optimistic about its future prospects. With losses projected throughout 2013, it’s unclear why shareholders remain excited about the stock. Yet a share-price advance of more than 30% suggests hope for better news in the future.
Dendreon has given investors an up-and-down ride over its history, as early expectations for Provenge turned out to be overly optimistic. In fact, on several occasions last year, Provenge actually saw sales fall sequentially from quarter to quarter. This quarter’s estimate is for modest growth, but at nothing like the pace investors had hoped for when Provenge got FDA approval.